Chardan Capital Reiterates “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $212.00 target price on the stock. Chardan Capital’s price target suggests a potential upside of 29.55% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Stifel Nicolaus boosted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average target price of $206.67.

Krystal Biotech Trading Down 5.6 %

Shares of KRYS opened at $163.64 on Thursday. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34. The firm has a market capitalization of $4.71 billion, a P/E ratio of 92.45 and a beta of 0.80. The stock’s fifty day simple moving average is $181.54 and its 200 day simple moving average is $184.87.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period last year, the business posted ($0.67) EPS. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. Sell-side analysts predict that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 14.10% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds have recently made changes to their positions in KRYS. Franklin Resources Inc. boosted its stake in Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech in the third quarter valued at about $40,000. Teachers Retirement System of The State of Kentucky raised its stake in Krystal Biotech by 198.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company’s stock valued at $1,640,000 after buying an additional 5,989 shares in the last quarter. Geode Capital Management LLC raised its stake in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after buying an additional 11,411 shares in the last quarter. Finally, Main Management ETF Advisors LLC acquired a new position in shares of Krystal Biotech in the 3rd quarter worth approximately $706,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).